Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its
subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement
to provide Lexaria’s patented DehydraTECH(TM) technology to a private
California-based cannabis company. Under the agreement the cannabis company
will utilize the technology in certain cannabis-based beverages to be produced
and sold in the states of California and Nevada. DehydraTECH-enabled beverages
are protected under Lexaria’s many existing US-granted patents and may include
any combination of ready-to-drink beverages such as non-alcoholic beers, wines
and spirits; cold or hot coffee or teas, sports drinks and much more. In
addition, Lexaria this morning announced the addition of Dr. Dwayne Godwin, Dr.
Terry D. Blumenthal, Dr. Matthew Fraser and Dr. Carla Lema Tome to its
Scientific Advisory Board. Each of the new appointees will contribute support,
advice and recommendations related to the company’s scientific research and
product development. “Lexaria Bioscience Corp. is very pleased to welcome these
accomplished experts to our Advisory Board, who can provide critical scientific
guidance to Lexaria’s ongoing and future R&D programs,” Lexaria CEO Chris
Bunka said in the news release. “Lexaria is building towards becoming one of
the world’s leaders in drug delivery technology and our most recent Advisors
can assist in achieving that goal.”
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and important
taste-masking benefits for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment